Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically
Autore:
Rusch, VW; Venkatraman, ES;
Indirizzi:
Mem Sloan Kettering Canc Ctr, Thorac Serv, Dept Surg, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr New York NY USA 10021 New York, NY 10021 USA Mem Sloan Kettering Canc Ctr, Biostat Serv, Dept Epidemiol & Biostat, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr New York NY USA 10021 New York, NY 10021 USA
Titolo Testata:
ANNALS OF THORACIC SURGERY
fascicolo: 5, volume: 68, anno: 1999,
pagine: 1799 - 1804
SICI:
0003-4975(199911)68:5<1799:IPFIPW>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXTRAPLEURAL PNEUMONECTOMY; MULTIMODALITY THERAPY; CONSECUTIVE PATIENTS; DIFFUSE; CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Rusch, VW Mem Sloan Kettering Canc Ctr, Thorac Serv, Dept Surg, 1275 York Ave,Rm C867, New York, NY 10021 USA Mem Sloan Kettering Canc Ctr 1275 York Ave,Rm C867 New York NY USA 10021
Citazione:
V.W. Rusch e E.S. Venkatraman, "Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically", ANN THORAC, 68(5), 1999, pp. 1799-1804

Abstract

Background. The factors influencing outcome after resection of malignant pleural mesothelioma (MPM) are controversial. This analysis of a prospectivesurgical database identifies important prognostic factors. Methods. Tumors were staged by the International Mesothelioma Interest Group staging system, and patients were followed until death. Prognostic factors were analyzed by log rank and Cox regression, and were considered significant if p was less than 0.05. Results. From Oct 1983 to May 1998, 231 patients underwent thoracotomy, 115 had extrapleural pneumonectomy (EPP), and 59 pleurectomy/decortication (P/D). Among patients having EPP or P/D, 142 received adjuvant therapy. The median survival for stage I tumors was 29.9 months, for stage II 19 months, for stage III 10.4 months, and for stage IV 8 months. By multivariate analysis, stage, histology, gender, adjuvant therapy, but not the type of surgical resection, were significant. Conclusions. The better survival previously reported for P/D compared withEPP is not seen in a large database with long follow-up. Stages I and II have better survival rates than generally assumed for MPM. Locally advanced T and N status, and nonepithelial histology, identify poor prognosis patients who should be considered for novel treatment regimens. (C) 1999 by The Society of Thoracic Surgeons.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 17:05:38